In this prospective randomized controlled blinded multicenter trial, a total of 120 high-risk cardiac surgery patients will receive either standard of care + OMEGAVEN at 0.20 g/kg ideal body weight (IBW) versus placebo + standard of care. conditions: Cardiac Surgery conditions: High Risk Patients conditions: Intensive Care Unit conditions: Cardiopulmonary Bypass conditions: Valve Surgeries studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization will be stratified by site, employing a web-based system using a 1:1 ratio to either intravenous FO- based lipid emulsion (Omegaven®), or placebo. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Researchers and clinical staff will be blinded to study intervention allocation. Unblinded delegate at each site will be able to prepare and dispense the investigational drug or placebo. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Long-chain n-3 fatty acids name: Intravenous 0.9% Sodium Chloride measure: Atrial fibrillation measure: Weaning from cardiopulmonary bypass (CPB) measure: Time to discharge alive measure: Persistent Organ Dysfunction + Death measure: Days alive and out of hospital measure: Hospital length of stay measure: ICU length of stay measure: Simplified Acute Physiology Score measure: Therapeutic Intervention Scoring System measure: ICU and Hospital Readmission rates measure: Delta Sequential Organ Failure Assessment Score (SOFA) Score measure: Mechanical ventilation measure: Stroke measure: Acute Kidney Injury measure: Infections rate measure: Clinical frailty scale measure: Development of delirium measure: Survival status measure: Physical activity assessment measure: Quality of Life (SF-36) measure: Adverse Events measure: Postoperative bleeding measure: Optional-Ultrasound measurement measure: Optional-Functional Status Score for Intensive Care Unit measure: Optional-Short Physical Performance Battery test measure: Optional-Hand grip dynamometer measure: Optional-Hand held dynamometer measure: Optional-Manual Muscle Testing measure: Optional-Left ventricular ejection function measure: Optional-Markers of inflammation measure: Optional-Hemodynamics measure: Sub-study sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RWTH Aachen University status: NOT_YET_RECRUITING city: Aachen country: Germany name: Moritz Immohr, M.D role: CONTACT email: mimmohr@ukaachen.de name: Aileen Hill, M.D role: CONTACT email: ahill@ukaachen.de lat: 50.77664 lon: 6.08342 facility: Charité Universitätsmedizin Berlin status: NOT_YET_RECRUITING city: Berlin country: Germany name: Sascha Ott, M.D role: CONTACT email: sascha.ott@dhzc-charite.de name: Maren Kleine-Brüggeney, M.D role: CONTACT email: maren.kleine-brueggeney@dhzc-charite.de lat: 52.52437 lon: 13.41053 facility: University of Bonn status: NOT_YET_RECRUITING city: Bonn country: Germany name: Markus Velten, M.D role: CONTACT email: markus.velten@ukbonn.de name: Maria Wittmann, M.D role: CONTACT email: Maria.Wittmann@ukbonn.de lat: 50.73438 lon: 7.09549 facility: Universität Göttingen status: NOT_YET_RECRUITING city: Göttingen country: Germany name: Reiner Wäschle, M.D role: CONTACT email: Reiner.Waeschle@med.uni-goettingen.de name: Anselm Bräuer, M.D. role: CONTACT email: abraeue@gwdg.de lat: 51.53443 lon: 9.93228 facility: University Medical Center Schleswig-Holstein status: NOT_YET_RECRUITING city: Kiel country: Germany name: Elke Gunnar, M.D role: CONTACT email: Gunnar.Elke@uksh.de name: Matthias Lindner, M.D role: CONTACT email: Matthias.Lindner@uksh.de lat: 54.32133 lon: 10.13489 facility: University of Muenster status: RECRUITING city: Münster country: Germany name: Alexander Zarbock, M.D role: CONTACT email: zarbock@uni-muenster.de name: Carola Wempe, M.D role: CONTACT email: Carola.Wempe@ukmuenster.de lat: 51.96236 lon: 7.62571 hasResults: False